Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline and Letrozole for Ovulation Induction in PCOS
NCT07255911Recruiting
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cabergoline in polycystic ovary syndrome (PCOS) and infertility (2 arms). Primary endpoint: Ovulation Rate up to 12 weeks. Started Feb 2025; status: recruiting.
02
Drugs
cabergoline
03
Conditions
polycystic ovary syndrome (PCOS)infertility
Beyond the preview
Go deeper on NCT07255911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07255911.